The full text of the letter to Collins follows:
June 16, 2014
Dr. Francis S. Collins
National Institutes of Health
Building 1, One Center Drive
Bethesda, MD 20892-0160
Dear Dr. Collins:
Thank you for your renewed efforts to spur medial advancements in Parkinson's disease research. The recent two-day conference held by the National Institute of Neurological Disorders and Stroke, Parkinson's Disease 2014: Advancing Research, Improving Lives, and the stakeholder planning meeting at the beginning of this year, demonstrate NIH's commitment to doing everything possible to treat and understand Parkinson's.
As you set priorities for the next phase of the Accelerating Medicines Partnership (AMP) we encourage you to expand the projects to include Parkinson's disease. The discovery of biomarkers for this disease would help in both earlier diagnosis and drug development. The strength of this program is in bringing together federal agencies, biopharmaceutical companies, and stakeholder organizations to facilitate drug development and diagnostics. Even though Parkinson's disease is the second most common neurological disease in the United States, currently there is no cure, therapy, or drug that slows or halts the progression of the disease.
It is clear that there is work to be done and the new approaches underway through the AMP program could have a very positive impact on Parkinson's research.
Thank you for your consideration. We look forward to your response.